Please use this identifier to cite or link to this item: https://idr.l1.nitk.ac.in/jspui/handle/123456789/13203
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNayak, N.-
dc.contributor.authorRamprasad, J.-
dc.contributor.authorUdayakumar, D.-
dc.contributor.authorYogeeswari, P.-
dc.contributor.authorSriram, D.-
dc.date.accessioned2020-03-31T08:45:23Z-
dc.date.available2020-03-31T08:45:23Z-
dc.date.issued2016-
dc.identifier.citationChinese Chemical Letters, 2016, Vol.27, 3, pp.365-369en_US
dc.identifier.urihttps://idr.nitk.ac.in/jspui/handle/123456789/13203-
dc.description.abstractThis article demonstrates the synthesis, characterization and the study of in vitro antitubercular activities of twenty four new N-(4-(5-aryl-3-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazol-1-yl)phenyl)-4-amide derivatives (8a-x). The antitubercular activity of the compounds against Mycobacterium tuberculosis H37Rv (MTB) revealed that 2-chloro-N-(4-(5-(4-chlorophenyl)-3-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazol-1-yl)phenyl)benzamide (8n) is the most promising lead molecule with a MIC of 1.56 ?g/mL, while the corresponding unsubstituted benzamide derivative (8o) is the next most active molecule with a MIC of 3.13 ?g/mL. Interestingly, the pyrazole intermediate 5b containing chlorophenyl and N-acylcarbohydrazide substituents also showed significant activity (MIC = 3.13 ?g/mL). Further, the active molecules did not show toxicity against a normal NIH 3T3 cell line, signifying their suitability for further drug development. 2016 Udayakumar Dalimba.en_US
dc.titleSynthesis and antimycobacterial screening of new N-(4-(5-aryl-3-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazol-1-yl)phenyl)-4-amide derivativesen_US
dc.typeArticleen_US
Appears in Collections:1. Journal Articles

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.